...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiovascular medicine >Long-term outcomes after transcatheter aortic valve replacement in nonagenarians: a multicenter age-based analysis
【24h】

Long-term outcomes after transcatheter aortic valve replacement in nonagenarians: a multicenter age-based analysis

机译：经齿轮管主动脉瓣膜置换后长期成果在珠锐利：多中心基于年龄的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim To assess the outcome of nonagenarians patients receiving transcatheter aortic valve replacement (TAVR). Methods We aimed to stratify the overall population from an Italian, multicenter, observational project including a total of 3792 consecutive patients who underwent TAVR with CoreValve and Evolut R/PRO devices between April 2009 and October 2018, into four groups according to their age class (≥90 vs. 80–89 years vs. 70–79 vs. <70 years) and to compare outcomes up to 4 years after TAVR. Results At 4 years, survival estimates showed no difference in terms of overall survival [Kaplan–Meier estimates (KM est.) 49.9 vs. 58.1% vs. 57.0 vs. 69.3%; P _(logrank)?=?0.28] among the four groups. After 2 years from the procedure, landmark analysis showed an age-based difference in overall survival (KM est. 63.8 vs. 75.0% vs. 75.1 vs. 88.7%; P _(logrank)?=?0.025) but no difference in terms of survival from cardiovascular death (KM est. 87.8 vs. 87.4% vs. 86.1 vs. 96.1%; P _(logrank)?=?0.43). Finally, age itself was not correlated with overall mortality at 4 years (hazard ratio 1.06, 95% confidence interval 0.86–1.30, P ?=?0.591). Conclusion TAVR with self-expanding CoreValve and Evolut prostheses was demonstrated to have good long-term outcomes, regardless of the patient's age. At 4 years, no difference in overall mortality was reported among age-based groups, while a higher overall mortality was reported in nonagenarians after 2 years from the procedure. TAVR showed good long-term outcomes even in nonagenarian patients, and it could be the therapy of choice for selected elderly patients.
机译：目的评估接受经导管主动脉瓣置换术（TAVR）的90岁患者的预后。方法我们旨在将意大利多中心观察性项目的总体人群按年龄分类，将2009年4月至2018年10月期间使用CoreValve和Evolut R/PRO设备进行TAVR的3792名连续患者分为四组(≥90岁与80-89岁与70-79岁与<70岁）并比较TAVR后4年的结果。结果在4年时，生存率估计在总生存率方面没有差异[Kaplan–Meier估计（KM est.）49.9%对58.1%对57.0%对69.3%；P（对数秩）？=？在四组中为0.28]。术后2年，landmark分析显示总生存率存在年龄差异（KM est.63.8 vs.75.0%vs.75.1 vs.88.7%；P(logrank)）=？0.025），但在心血管死亡的存活率方面没有差异（KM est.87.8 vs.87.4 vs.86.1 vs.96.1%；P（logrank）？=？0.43）。最后，年龄本身与4岁时的总体死亡率无关（危险比1.06，95%置信区间0.86–1.30，P？=0.591）。结论无论患者年龄大小，采用自膨胀核心瓣膜和Evolut假体的TAVR均具有良好的长期疗效。4岁时，不同年龄组的总死亡率没有差异，而在手术2年后，九岁组的总死亡率更高。TAVR即使在非老年患者中也显示出良好的长期疗效，并且它可能是选定老年患者的首选治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号